Targeting p53 by small molecules in hematological malignancies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The p53 protein is a crucial tumor suppressor with significant therapeutic potential in cancer treatment.
• Many existing and novel anti-cancer therapies function by enhancing the anti-proliferative functions of p53.

Purpose of the Study:

• To review recent advancements in utilizing small molecules to target p53 in hematological malignancies.
• To discuss the anticancer activities and mechanisms of action of various compounds that activate the p53 signaling pathway.

Main Methods:

• Literature review of studies on small molecules targeting p53 in hematological cancers.
• Analysis of the anticancer activity and mechanisms of action of different classes of p53-activating compounds.

Main Results:

• Small molecules like nutlin, RITA, and PRIMA-1 demonstrate anti-tumor effects in hematological malignancies by activating p53.
• Nutlin and PRIMA-1 have progressed to Phase I/II clinical trials for specific hematological cancers.

Conclusions:

• Pharmacological activation of p53 using small molecules has a significant clinical impact on prognosis and targeted drug development.
• The p53 tumor suppressor protein represents a promising target for current and future novel therapies in hematological diseases.